IGM Biosciences, Inc.
IGMSNASDAQHealthcare
$1.27
+$0.00(+0.00%)
Market Cap$77498317
P/E Ratio—
52W High$22.5
52W Low$0.92
IGM Biosciences, Inc. (IGMS) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · IGMS · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $2.68M | $2.13M | $1.07M | $0.00M | $0.00M |
| Cost of Revenue | $9.11M | $8.28M | $10.60M | $7.72M | $3.58M |
| Gross Profit | ($6.43M) | ($6.15M) | ($9.53M) | ($7.72M) | ($3.58M) |
| Gross Margin %(computed) | -240.13% | -288.59% | -891.77% | — | — |
| Operating Expenses | |||||
| R&D Expenses | $160.85M | $215.52M | $179.29M | $127.03M | $65.03M |
| G&A Expenses | $50.41M | $50.07M | $49.74M | $38.30M | $18.25M |
| Total Operating Expenses | $211.26M | $265.59M | $229.03M | $165.32M | $83.28M |
| Operating Income | ($208.58M) | ($263.46M) | ($227.96M) | ($165.32M) | ($83.28M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $12.79M | $17.74M | $7.04M | $0.16M | $1.93M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($195.79M) | ($245.74M) | ($221.10M) | ($165.16M) | ($81.36M) |
| Income Tax Expense | $0.00M | $0.68M | $0.00M | $0.00M | $0.00M |
| Net Income | ($195.79M) | ($246.42M) | ($214.25M) | ($160.68M) | ($80.33M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.24 | $-4.71 | $-5.16 | $-4.80 | $-2.61 |
| Wtd Avg Shares | 60.51M | 52.31M | 41.54M | 33.48M | 30.75M |
| EBITDA | ($199.47M) | ($255.18M) | ($221.88M) | ($157.44M) | ($77.78M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more IGM Biosciences, Inc. data
About IGM Biosciences, Inc. (IGMS) Income Statement
IGM Biosciences, Inc. (IGMS) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2024, IGMS reported revenue of $0.00B, gross profit of ($0.01B) (gross margin -240.13%), and net income of ($0.20B) — a net profit margin of -7308.51%.
Frequently asked questions
IGMS · 4 questionsIGM Biosciences, Inc. (IGMS) reported revenue of $0.00B for 2024, up 25.8% year-over-year.
IGMS revenueIGMS salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09